Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?

Simply Wall St.06-21

In its latest quarterly update, Collegium Pharmaceutical reported year-over-year revenue growth of 8.87% and a very large increase in net profit, alongside strong financial scores for profitability, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645092541?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-06-21 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645092541","market":"hk","top_or_hot":-1,"title":"Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>In its latest quarterly update, Collegium Pharmaceutical reported year-over-year revenue growth of 8.87% and a very large increase in net profit, alongside strong financial scores for profitability, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-21 13:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In its latest quarterly update, Collegium Pharmaceutical reported year-over-year revenue growth of 8.87% and a very large increase in net profit, alongside strong financial scores for profitability, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARTY","symbol_name":"ISHARES FUTURE AI & TECH ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici","article_id":"2645092541","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645092541","pubTimestamp":1782019349,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In its latest quarterly update, Collegium Pharmaceutical reported year-over-year revenue growth of 8.87% and a very large increase in net profit, alongside strong financial scores for profitability, operational efficiency, and growth potential.\nThese results suggest recent spending and operational adjustments are starting to translate into much stronger earnings power, easing earlier concerns about whether the company’s investments would improve profitability.\nNow we’ll examine how this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARTY":"ISHARES FUTURE AI & TECH ETF","AIPO":"Defiance AI and Power Infrastructure ETF","COLL":"Collegium Pharmaceutical, Inc.","AGIX":"通用人工智能 ETF-AGIX","BK4007":"制药","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF"},"translate_title":"Collegium Pharmaceutical的盈利能力飙升和效率提高是否只是改变了COLL的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHAT":0.71,"ARTY":0.71,"COLL":1.5,"AGIX":0.71,"AIPO":0.82},"content_text":"In its latest quarterly update, Collegium Pharmaceutical reported year-over-year revenue growth of 8.87% and a very large increase in net profit, alongside strong financial scores for profitability, operational efficiency, and growth potential. These results suggest recent spending and operational adjustments are starting to translate into much stronger earnings power, easing earlier concerns about whether the company’s investments would improve profitability. Now we’ll examine how this sharp improvement in profitability and efficiency affects Collegium Pharmaceutical’s existing investment narrative and risk-reward profile. Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementCollegium Pharmaceutical Investment Narrative RecapTo own Collegium Pharmaceutical, you need to believe its focused pain portfolio can keep generating solid cash flows while management improves efficiency faster than competitive and regulatory pressures build. The latest quarter’s sharp profit improvement supports the near term earnings catalyst by showing recent spending is translating into stronger margins, but it does not remove the key risk around future generic competition and pricing pressure on its core opioid-based products. Among recent developments, Collegium’s reaffirmed full year 2026 revenue guidance of US$805 million to US$825 million stands out, because it ties the improved profitability directly to concrete revenue expectations in the near term. That guidance now sits alongside a higher net profit base and better efficiency scores, giving investors a clearer line of sight on how current operations could support the company through looming patent, payer, and regulatory headwinds. Yet behind these improving numbers, investors still need to watch the growing risk that generic competition and payer pressure could start to erode... Read the full narrative on Collegium Pharmaceutical (it's free!)Collegium Pharmaceutical's narrative projects $852.4 million revenue and $242.8 million earnings by 2029.Uncover how Collegium Pharmaceutical's forecasts yield a $54.33 fair value, a 62% upside to its current price.Exploring Other PerspectivesCOLL 1-Year Stock Price Chart Two Simply Wall St Community fair value estimates for Collegium span from US$54.33 to an extreme US$496.29, underlining how far apart individual views can be. When you set those views against the recent profitability surge and reaffirmed revenue guidance, it becomes even more important to compare different expectations for how long Collegium’s pain portfolio can sustain its current earnings power.Explore 2 other fair value estimates on Collegium Pharmaceutical - why the stock might be a potential multi-bagger!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Collegium Pharmaceutical research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.Our free Collegium Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Collegium Pharmaceutical's overall financial health at a glance.Seeking Other Investments?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645092541","isCrawlerRequest":true}